Pediatrix Medical Group, Inc 8-K, filed Mar 8, 2023
Pediatrix Medical Group, Inc. (MD)
About this 8-K
Pediatrix Medical Group, Inc filed this 8-K on March 8, 2023, reporting on events of March 7, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 8, 2023, the Board of Directors (the “Board”) of Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), elected James D. Swift, M.D., the Company’s Chief Executive Officer, to the Board to fill a vacancy created by the resignation of Roger J. Medel M.D., who resigned from the Board effective March 7, 2023. Dr. Medel’s resignation was not the result of any disagreement between the Company and Dr. Medel, known to an executive officer of the Company, on any matter relating to the Company’s operations, policies, or practices.
Directors who are also employees of the Company, including Dr. Swift, receive no additional compensation for serving as directors. Dr. Swift is not a party to any arrangement or understanding with any person pursuant to which he was elected as a director, nor is he a party to any transaction required to be disclosed under Item 404(a) of Regulation S-K involving the Company that has not previously been disclosed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Pediatrix Medical Group, Inc. |
|
|
|
|
Date: |
March 8, 2023 |
By: |
/s/ C. Marc Richards |
|
|
|
C. Marc Richards |